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Cushing’s syndrome (CS) is a classical rare disease: it is often suspected in patients
who do not have the disease; at the same time, it takes a mean of 3 years to diagnose
CS in affected individuals. The main reason is the extreme rarity (1–3/million/year)
in combination with the lack of a single lead symptom. CS has to be suspected
when a combination of signs and symptoms is present, which together make up
the characteristic phenotype of cortisol excess. Unusual fat distribution affecting the
face, neck, and trunk; skin changes including plethora, acne, hirsutism, livid striae,
and easy bruising; and signs of protein catabolism such as thinned and vulnerable
skin, osteoporotic fractures, and proximal myopathy indicate the need for biochemical
screening for CS. In contrast, common symptoms like hypertension, weight gain, or
diabetes also occur quite frequently in the general population and per se do not justify
biochemical testing. First-line screening tests include urinary free cortisol excretion,
dexamethasone suppression testing, and late-night salivary cortisol measurements.
All three tests have overall reasonable sensitivity and specificity, and first-line testing
should be selected on the basis of the physiologic conditions of the patient, drug
intake, and available laboratory quality control measures. Two normal test results usually
exclude the presence of CS. Other tests and laboratory parameters like the high-dose
dexamethasone suppression test, plasma ACTH, the CRH test, and the bilateral inferior
petrosal sinus sampling are not part of the initial biochemical screening. As a general
rule, biochemical screening should only be performed if the pre-test probability for
CS is reasonably high. This article provides an overview about the current standard
in the diagnosis of CS starting with clinical scores and screenings, the clinical signs,
relevant differential diagnoses, the first-line biochemical screening, and ending with a
few exceptional cases.
Keywords: Cushing’s syndrome, hypercortisolism, diagnostic score, Cushing’s disease,
low-dose-dexamethasone-suppression-test, urine cortisol
INCIDENCE, EPIDEMIOLOGY, AND TIME TO DIAGNOSE CS
Cushing’s syndrome (CS) is a rare disease leading to atypical and rare symptoms for age, but it can
be associated with disease features that are quite common in the general population. The incidence
of endogenous CS has been estimated to be 0.7–2.4 to 0.2–5.0 per million people per year (1, 2).
About 80% of cases are ACTH-dependent, whereas 20% of Cushing cases are of primary adrenal,
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ACTH-independent origin. ACTH-dependent CS can be further
divided into pituitary-dependent CS and ectopic, paraneoplastic
CS. While the latter is quite seldom, causing not more
than 10% of cases, CRH-producing tumors account for
even fewer cases (3). Because of the universal expression
of the glucocorticoid receptor, the list of symptoms and
clinical signs is long and lacks a clear focus. This, and the
overlap with symptoms of the metabolic syndrome, makes
diagnostics challenging.
The rareness of the disease, the broad symptomatology
without a lead symptom, and the clinical overlap with features
of the metabolic syndrome often results in a delayed diagnosis.
Generally, it can take up to 4 years and longer from the
beginning of disease symptoms to the actual diagnosis (4). On
average, 4.6 physicians will have to be consulted according to
one study (4). This is hardly acceptable, considering that CS
is an endocrinological “emergency” associated with relevant
morbidity and mortality. Mortality is highest in patients with
severe hypercortisolism and persisting and ectopic CS (5), and
a relevant number of patients die before or within 90 days
after initiation of treatment (6). The diagnostic delay might
be one of the reasons for the long-term negative aspects
and comorbidities (7–9) and high morbidity in these patients
even after achieving remission of the actual disease. We have
recently analyzed in a systematic meta-analysis of 45 studies
on 5,560 patients with CS time to diagnosis and found that
it has remained unchanged with a mean time of 34 months
(10). This clearly argues for considerations beyond established
awareness campaigns. New approaches including automated
face recognition, easy-to-apply scoring systems, or focused
rational diagnostics will be instrumental to overcome the current
challenges. In the following, we will give a critical overview of
the current standard in the diagnosis of CS, mainly focusing
on the prevalence of different clinical symptoms in patients
with CS.
CLINICAL REASONING PROBLEMS
Solving clinical cases correctly (11)—but also efficiently (12)—
is one of the great challenges in daily clinical practice.
Diagnostic error rate in internal medicine is generally high (at
least 10%) (13) due to a lack of knowledge (14), premature
closure, and forgetting to consider other diagnoses (15). As
Clinical Reasoning is mainly based on pattern recognition
and illness script formation (16, 17), it is quite clear that
diagnosing CS correctly is even more challenging than many
other diseases: statistically, a family practitioner diagnoses
between 0 and 1 patient with CS in his work-life. Even
endocrinologists seldom diagnose patients with CS, apart from
endocrinologists in specialized outpatient clinics. Therefore,
as physicians will only evaluate a small number of true
Cushing patients, it is difficult for them to develop the
corresponding illness scripts to diagnose the disease in time.
To foster the clinical reasoning process, different attempts have
been made.
ATTEMPTS TO FASTEN THE DIAGNOSTIC
PROCESS
As the pretest probability is generally low because of the
rareness of CS, it is mandatory to preselect patients with an
appropriate likelihood of endogenous CS and use laboratory
tests with high sensitivity and specificity. Different strategies
starting from clinical scores, face recognition, and ending with
extended screening have been used in the past decades to improve
differential diagnostics:
Clinical Scores for CS
As early as 1964, Nugent et al. developed a clinical score
to identify patients with CS (18) correctly. To simplify the
diagnostic process, he used a combination of clinical signs
and symptoms to discriminate patients with hypercortisolism
from patients without it. The following 19 signs are part of
his scoring: osteoporosis, central obesity, generalized obesity
(muscle) weakness, plethora, WBC (white blood cells), acne, red
and purple striae, diastolic blood pressure, edema, hirsutism,
ecchymoses, serum potassium, oligomenorrhea, headaches,
MCV, abnormal glucose tolerance, and age. However, only
half of the patients with CS can be correctly identified using
this scoring, and therefore, the score was not adapted into
clinical routine. Importantly, “Cushing symptoms”—and even
the combination of these symptoms—occur quite frequently in
the general population (see Table 1).
More recently, Leon-Justel et al. developed a risk scoring
system based on a prospective multicenter screening of 353
patients. Thirteen university hospitals in Spain took part in
the study. All these patients consulted an endocrinologist due
to different medical problems but not with the suspicion of
CS. Patients were included in the screening when they had
at least two of the following symptoms: obesity, a poorly
controlled blood pressure, an uncontrolled diabetes, virilization
syndrome, or osteoporosis. For screening purposes, the late-night
salivary cortisol and the low-dose dexamethasone suppression
test (LDDST) were used. Finally, 26 patients with CS were
identified among this cohort (7.4%). Diagnosis was confirmed
by a full biochemical screening and follow-up. The clinical
features of patients with CS and patients without it were
compared. In a univariate analysis, three clinical signs were
significantly associated with CS: muscular atrophy, osteoporosis,
and dorsocervical fat pad. Two clinical signs—obesity and type
2 diabetes—were more common in patients without a CS than
in patients with CS. Different statistical models were studied,
leading to a final score with just three clinical signs and
one laboratory parameter: osteoporosis, dorsocervical fat pad,
muscular atrophy, and late-night salivary cortisol levels (47).
Muscular atrophy is higher scored than the other two clinical
parameters, while salivary cortisol is divided into low, medium,
and high with different scores. The maximum is a score of 12
points. The final form was as follows:
Risk for CS = 2 × presence of osteoporosis (yes/no) + 2 ×
dorsocervical fat pad (yes/no) + 3 ×muscular atrophy (yes/no) +
late-night salivary cortisol (low= 0, medium= 4, high= 5). Using
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TABLE 1 | Clinical symptoms in Cushing’s syndrome [*Prevalence in Cushing’s
syndrome adapted from Valassi et al. (19), Sharma et al. (20), Feelders et al. (21),
and Newell-Price et al. (2)] and in the general population.
Symptom Prevalence in
Cushing’s syndrome*
Prevalence in the general
population
OBJECTIVELY ASSESSABLE
Recent weight gain 70–95% Up to 50% (22)
Overweight 21–48% 50%
Obesity 32–41% 20%
Hypertension (blood
pressure > 140/90mm
mercury)
58–85% Up to 44% (23)
Abnormal glucose
tolerance
21–64% 7.4–16.4% (24)
Diabetes mellitus 20–47% Age-dependent; 2–22% (25)
Osteopenia 60–80% Dependent on age, sex; up to
30% in postmenopausal
women (26), quite seldom in
young men and women
Osteoporosis 31–50%
Osteoporotic fractures Asymptomatic fractures
up to 80%
Proximal muscle
weakness, myopathy
60–82% Unclear, dependent on
medication, neurological
diseases, and alcohol abuse
Dyslipidemia 38–71% 22% (27)
Purple striae 78% (children) In healthy men: 11% (28)
Hypercoagulopathy
(hemostatic
abnormalities)
54% Variable dependent on
diseases
Atherosclerotic
changes
27–31% 25% (29)
Round face 81–90% Unclear
Plethora 70–90% Unclear
Buffalo hump 50% Unclear
Acne 59% (children) 12% in women, 3% in men
(30)
Hirsutism 56–75% Unclear, dependent on other
diseases and ethnic, up to
83% in PCOS (31)
Stroke 6% Age- and sex-dependent,
32–99/100.000/year (32)
Myocardial infarction 2% About 5% lifetime-risk (33)
Major depression 50–81% 10–20% (34)
Lethargy, depression,
labile mood
36%, maybe up to 80%
(35)
Up to 50% in elderly people
(36)
Cognitive changes Prevalence unclear, but
cognitive impairments
are frequent even over
the long-term (37)
Unclear
Hypocampal atrophy 27% (38) High in patients with dementia
or Alzheimer’s disease,
unclear in the younger
population
Thrombosis Incidence:
2.5–14.6/1,000
persons/year
Incidence: 1/1,000; higher in
older people (39)
Lung embolism 4% 0,5/1.000 (40)
(Continued)
TABLE 1 | Continued
Symptom Prevalence in
Cushing’s syndrome*
Prevalence in the general
population
Nephrolithiasis 20–50% 1–20% (dependent on
country) (41)
Thin skin 37% Unclear
Lack of vitamin D Unclear, but at least as
frequent as in the
general population
40–100% (42)
Edema Unclear Dependent on disease
Decreased growth in
children
70–80% 3%
Asymptomatic urinary
tract infections
Unclear Very common (43)
Sleeping disorder,
fatigue
60% Up to 25% (44)
Easy bruising 35–65% Unclear
Decreased libido 24–80% 29% (women) (45)
Poor wound healing Unclear Unclear
Menstrual changes
(women)
70–80% Dependent on illness
Hair loss 31% Up to 65% (46)
4 points as a cutoff, sensitivity of this score is 96% and specificity is
83% (47).
This score is quite promising, as false-negative results are
rare. However, specificity is not sufficiently high, so that
further tests have to be conducted to confirm or exclude the
diagnosis. Additionally, it is not described if muscular atrophy
and osteoporosis were assessed objectively (for example, by a
densitometry of a hand-grip test for muscle strength) or just by
the medical history.
Automated Face Recognition
Face classification was primarily used to identify patients with
acromegaly, for example, in a study by Learned-Miller et al. in
2006 (48). In a more recent study, accuracy rates up to 72% were
achieved. Especially in patients with less-severe diseases, software
classification outperformed medical experts significantly (49).
Face classification was also already used to distinguish
between patients with CS and patients with metabolic syndrome,
but only exploratively in a small cohort (50). Automatic face
classification can detect CS in 85% of patients correctly and
excludes the disease in 95% correctly. However, further studies
with BMI-matched controls are needed to evaluate the use of
automatic face recognition in CS (51). In a recent follow-up
study, we enrolled 82 patients (22 male, 60 female) and 98
control subjects (32 male, 66 female) rigidly matched by age,
gender, and body mass index. The control group consisted of
patients with initially suspected, but biochemically excluded CS.
The images were analyzed using specialized computer vision
and classification software. The overall correct classification
rates were 46 and 81% for male patients and controls, and 57
and 65% for female patients and controls, respectively. This
moderate diagnostic accuracy is probably related to the clinical
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characteristics of the control group (“rule-out CS patients”) who
have shown some signs of CS, whereas discrimination form a
normal control group would have been more efficient (52).
Extended Screening Approach for CS
Another screening approach to shorten time to diagnosis has
been based on the assumption that the disease may be prevalent
in an early form in certain at-risk population, such as the
metabolic syndrome. It was based on the rationale that the
prevalence of CS is expected to be high and screening those
patient cohorts might detect cases in an oligosymptomatic
state allowing before evolution of full-blown phenotype. Typical
patient cohorts screened were patients with type 2 diabetes,
uncontrolled hypertension, osteoporosis, or advanced metabolic
syndrome. This concept, initially promoted by data from small
studies with selection bias, has been called into question since the
incidence of CS was quite low in extended studies.
In unselected patients with diabetes mellitus type 2, CS is very
rare. In a study by Reimondo et al., a group of 100 patients
with newly diagnosed diabetes mellitus was screened for CS.
One patient had biochemical evidence of hypercortisolism but
without any clinical features (53). In a study by Mullan et al.,
79 controls and 201 patients with diabetes were screened for
CS. None of these patients was diagnosed with CS (54). In a
large multicenter study in Italy, 813 patients with diabetes were
screened. 0.6% (6 persons) had a hypercortisolism but only four
of them were successfully cured from CS by surgery (55). In
altogether seven studies, a prevalence between 0 and 3% was
reported (56).
In two studies, the prevalence of CS among patients with
hypertension has been analyzed: a study from the US identified
CS in 0.5% of 4,429 patients (57). In a study from Japan, over
1,000 patients were screened and about 1% were diagnosed with
CS (58).
Surprisingly, 10% of patients with obesity were diagnosed
with CS in one study (59), but these results are probably not
reliable as standard screening tests can be falsely positive in
very obese patients (60). The results of screening studies among
obese patients are very controversial, most likely due to different
methodological flaws in these studies according to a systematic
literature review by Tabarin and Perez (56). All in all, screening
for CS in this group does not seem to be efficient.
However, there are two groups, in which screening for CS
is actually reasonable: young patients with osteoporosis and
patients with adrenal incidentaloma.
CS is quite common in patients with osteoporosis and
vertebral fractures: about 5% of these patients have CS, mostly
caused by an adrenal adenoma (61). In another study with 219
patients, 11% of patients with vertebral fractures and a T score
lower than 2.5 suffered from CS (62). Patients with an adrenal
incidentaloma are another group, where standardized screening
for CS is endorsed by current guidelines, as on average 5% of
the patients have an autonomous cortisol secretion (63), in some
studies even up to 10% (64). Screening studies for patients with
depression are not available.
In conclusion, widespread screening appears to be neither
efficient nor indicated. The prevalence of the metabolic
TABLE 2 | States of physiologic hypercortisolism (66, 67).
Causes Prevalence of the condition in target populations
• Pregnancy –
• Depression 8.6% (34) in general population
• Alcohol dependence 4.7% (68) in general population
• Glucocorticoid
resistance
Unclear, but probably quite seldom
• Obesity 20% (US) in general population, dependent on country
(22)
• Diabetes mellitus 6.4% (estimated) in general population (25)
• Physical stress Unclear
• Malnutrition Up to 40% in hospitalized patients (69)
• CBG excess Unclear
syndrome among US-Americans is 22%. This is far more
often than CS, even if the prevalence of the disease might
be underestimated (65). Therefore, testing every patient with
metabolic syndrome is uneconomical and inefficient and would
be associated with an unreasonable number of false-positive
results. Finally, physiological forms of hypercortisolism are quite
common in a variety of conditions and diseases. Most of
them are far more common than CS (see Table 2). However,
biochemical testing may be indistinguishable from true CS.
This reinforces the paradigm that the confirmed diagnosis of
Cushing’s syndromes requires both a clinical phenotype and
biochemical confirmation.
GUIDELINES FOR SCREENING
There are only few guidelines regarding CS. The US Endocrine
Society Practice guideline recommends a restricted screening
approach for CS in the following instances (66):
• Patients with many clinical signs and symptoms that are
typical for CS should be further tested.
• Patients with symptoms that are unusual for their age should
be screened.
• Exceptional cases are children with diminished growth and
increasing weight. CS should be considered early to avoid short
stature in those children.
• Additionally, patients with an adrenal incidentaloma that
could be an adenoma should be screened.
• In all other patient groups, regular screening is
not recommended.
CLINICAL SIGNS AND SYMPTOMS
Many symptoms can go along with CS. Some of them are very
common but not very specific, while others are quite specific
but not common. Upfront, it is essential to realize that neither
the appearance of a single symptom can by itself prove the
disease nor the lack of a particular sign can exclude it. In
the clinical reasoning process, the entire clinical appearance
should be taken into account. The duration and extent of
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the disease influence the clinical symptomatology (2). Also,
sex and age affect clinical presentation (70). That explains the
different appearance of patients with the same disease. A few
symptoms can be helpful to discriminate patients with metabolic
syndrome from CS. Most of them are related to increased
protein breakdown due to the underlying catabolic state in
hypercortisolism: wide purple striae, plethora, proximal muscle
weakness, easy bruising (without a cause), and osteoporosis
(without any other reason) (21, 67). In particular, patients
with severe CS suffer from proximal muscle weakness and
purple striae.
CLINICAL REASONING SHOULD BE
SIMPLIFIED ACCORDING TO THE
FOLLOWING PRINCIPLES
There are symptoms and signs that are quite typical for patients
with CS as they seldom occur in healthy patients or patients with
different diseases:
• Careful inspection of the skin: whereas no patient with CS has
all symptoms, it is extremely likely that there will be at least
some of the following skin changes (purple striae, ecchymosis,
thin fragile skin, rubeosis, hirsutism, acne, impaired wound
healing) (2, 21, 67, 71). Purple striae: The prevalence of striae
among patients with CS is unclear, but lower than 50%. Its
appearance, however, is quite specific for this disease. Cushing
striae are livid and at least 1 cm wide. White, reddish, and
smaller striae can occur in patients with CS but are far
more often caused by obesity, pregnancy, or a fast growth in
childhood (72).
• Careful watch-out for signs and symptoms of protein
catabolism: Proximal muscle weakness (60–82%) affects
usually the muscles of the thighs; patients have problems with
stair climbing or squats. As patients often do not discriminate
between problems climbing stairs caused by dyspnea or
muscle weakness, physicians have to ask these aspects quite
specifically when taking the history (73). Other catabolic signs
include atrophic thin skin and osteoporosis (see below).
• Plethora (70–90%) (21, 74): Plethora can also be caused by
mitral stenosis and different dermatological diseases (such as
rosacea or lupus, which generally produce distinct erythema).
Patients should be asked whether the color of their skin has
changed. Photos of the patient taken a few years ago can help
to determine the beginning of the hypercortisolism.
• Atypical fat distribution: in addition to intra-abdominal
fat accumulation, the patients have increased fat pads
in the buccal area (“moon face”), the neck, the fossa
supraclavicularis, and the upper back (“buffalo hump”).
• Atypical symptoms for a specific age can be a hint for
Cushing’s disease: this includes osteoporotic fractures in pre-
menopausal women and men under 50 years (prevalence up
to 80% in fluoride CS) (61, 75, 76) and early onset arterial
hypertension in patients below 40 years of age, after exclusion
of other conditions like hyperaldosteronism or renal arterial
stenosis (58).
Some symptoms can be caused by hypercortisolism, but
patients might not be aware of this and do not mention
them spontaneously:
• Change of taste perception and sense of smell.
• Cognitive changes, including forgetfulness (38).
DIFFERENTIAL DIAGNOSIS OF CUSHING
PHENOTYPES
All the clinical signs and symptoms mentioned above allow
a few differential diagnoses—most of them are much more
common than CS and should be considered and possibly
excluded (see Table 3). Common differential diagnoses are a
PCO syndrome in young women, the metabolic syndrome,
and depression. It can be difficult to distinguish between PCO
syndrome and CS. We recommend that young women should
undergo a gynecological examination. Also, androstenedione,
testosterone, and insulin should be measured. In doubt or
in biochemical unclear situations, a short-term follow-up
(exemplarily after 3 months) can be helpful to differentiate
the diagnoses. Depression and diabetes mellitus can also
cause mild hypercortisolism. In these cases, a sufficient
therapy (for example, with an anti-depressive medication) is
helpful to distinguish between diagnoses. Naturally, a careful
medication history should be taken to avoid overlooking an
exogenous CS.
GENERAL LAB RESULTS
A broad laboratory investigation should be conducted
as a few changes in laboratory parameters can occur in
patients with CS—frequencies unfortunately unclear—and
can be a first hint for a hypercortisolism (see Table 4).
Hypokalemia occurs in severe hypercortisolism (up to
100% in patients with ectopic CS, 5–10% in Cushing’s
disease) (77).
BIOCHEMICAL SCREENING FOR CS
The US Endocrine Society Practice guideline (66) recommends
three tests for biochemical screening: the 1-mg LDDST,
the 24-h urine cortisol (UFC) determination, and the late-
night salivary cortisol measurement. All other screening
methods, such as the 2-mg dexamethasone suppression test, the
midnight serum cortisol, or the desmopressin stimulation test,
either have a lower sensitivity or are challenging to perform
correctly. Therefore, these methods are not recommended
for initial screening purposes. Also, the measurement
of basal morning serum cortisol or basal ACTH is not
diagnostically conclusive because of the diurnal rhythm
with physiologically high morning levels. Only in severe cases
(for example in ectopic CS) are basal cortisol levels elevated on a
regular basis.
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TABLE 3 | Differential diagnosis of Cushing’s signs and symptoms.
Symptom/Sign Possible differential diagnosis (selection)
Increased visceral fat
tissue, weight gain
• Eating disorder
• Pregnancy
• Alcohol abuse
• PCO syndrome
• Seldom: genetic disorders
• Hypothyroidism
• Edema
• Medication
• Insulinoma
Hypertension • Essential hypertension
• Pheochromocytoma-
Paragangioma
syndrome
• Hyperthyroidism
• Medication
• Primary aldosteronism
• Renal artery stenosis
• Sleep apnea
• Renal hypertension
• Acromegaly
Impaired glucose
tolerance, diabetes
• Diabetes mellitus type 1
and 2
• Other endocrinological
disorders (hyperthyroidism,
acromegaly)
• Gestational diabetes
• Chronic pancreatitis
• Medication
• PCO syndrome
Proximal muscle
weakness, myopathy
• Age (sarcopenia)
• Alcohol abuse
Neurological disorders
Osteoporosis,
osteopenia, fractures
• Postmenopausal
osteoporosis
• Medication
• Primary
hyperparathyroidism
• Hyperthyroidism
• Senile osteoporosis
• Mastozytose
• Idiopathic
• Malabsorption
• Hypogonadism
Dyslipidemia • Lifestyle
• Diabetes mellitus
• Liver and renal diseases
• Familial forms
• Medication
• Alcohol abuse
• Obesity
Livid striae • Obesity
• Pregnancy
• Medication
• Idiopathic
Round face Obesity
Plethora • Rosacea
• Lupus
Mitral stenosis
Buffalo neck • Madelung Syndrome Obesity
Acne • PCO syndrome
• Medication
Idiopathic
Hirsutism • PCO syndrome
• Ovarian tumors
• Acromegaly
• Congenital adrenal
hyperplasia
• Medication
• Menopause
• Idiopathic
• Obesity
• Diabetes
Lethargy, depression,
labile mood
Depression Other psychiatric disorders
Cognitive changes • Depression
• Age
Dementia
Thrombosis, lung
embolism
• Provoked (e.g.,
immobilization)
• Genetic disorders
• Oral contraception
• Nicotine abuse
Nephrolithiasis Medication Nutrition
Thin skin • Age
• Diabetes mellitus
Medication
Edema • Heart insufficiency
• Lymphedema
Renal insufficiency, other
renal disorders
Sleeping disorder • Depression
• Sleep apnea
• Alcohol abuse
• Physical and
psychological stress
• Hyperthyroidism
Decreased libido • Depression
• Relationship problems
• Medication
• Adrenal insufficiency
• Physiological stress
• Alcohol consume
• Hypothyroidism
(Continued)
TABLE 3 | Continued
Symptom/Sign Possible differential diagnosis (selection)
Recurrent infections Other immune-deficiencies HIV infection
Poor wound healing • Malnutrition
• PAVK
• Medication
• Cancer
• Age
• Diabetes mellitus
• Nicotine abuse
• Anemia
Menstrual changes • PCO syndrome
• Hypo- and hyperthyroidism
• AGS
• Adrenal insufficiency
• Prolactionoma
• Pregnancy
• Menopause
• Medication
• Weight loss
• Anorexia
Hair loss • Androgenic alopecia
• Adrenal insufficiency
• Lupus
• Malnutrition
• Divers dermatologic
disorders
• Hyperparathyroidism
• Medication
TABLE 4 | Laboratory changes in patients with Cushing’s syndrome.
Lab parameter Differential diagnoses (selection)
Hypokalemia (77) Primary hyperaldosteronism, medication, renal diseases
Low testosterone (78) Medication, hypogonadism
Eosinopenia (79) Infections, stress, medication
Hypercalciuria (80) Hyperparathyroidism, vitamin D intoxication, bone
metastasis, sarcoidosis, idiopathic, renal resorption
disorders
Leucocytosis,
lymphopenia (81)
(Chronic) Infections, HIV, leukemia
Erythrocytosis (82) Hypoxemia, renal, paraneoplastic
SENSITIVITY AND SPECIFICITY OF
BIOCHEMICAL SCREENING TESTS
The abovementioned three screening tests all have a comparable
accuracy (93). At least two of the screening tests should be
performed. When two of them show an abnormal test result
AND the patient has a high pre-test probability by clinical
presentation, the diagnosis can be confirmed. The sensitivity
and the specificity of individual tests is highly depending on
factors such as the cutoffs and the assays used. Generally,
higher sensitivity can be reached by lower cutoffs, but decreasing
specificity—and the other way around. Sensitivity and specificity
are almost equal in all three screening tests (shown in Table 5).
However, not every test is as useful as the others in all patients
(see Tables 6, 7).
FALSE-POSITIVE AND FALSE-NEGATIVE
BIOCHEMICAL TEST RESULTS
Low-Dose Dexamethasone Suppression
Test
The LDDST can be falsely positive in women who take oral
contraception. Up to 50% of these women will have a positive
test result (3). The oral contraception causes an increased CBG,
which influences the test results (84). In these women, the
cortisol measurement in the urine is more helpful as CBG
Frontiers in Endocrinology | www.frontiersin.org 6 November 2019 | Volume 10 | Article 766
Braun et al. Diagnostics in Cushing’s Syndrome
TABLE 5 | Sensitivity and specificity of first-line screening [adapted from Nieman
et al. (66) and Reimondo et al. (83)].
Tests Sensitivity (%) Specificity (%) Cutoffs
Low-dose dexamethasone
suppression test
80–95 80–95 Depended
on assay
Urine free cortisol 45–71 Up to 100
Late-night salivary cortisol 92–100 85–100
TABLE 6 | Biochemical tests: causes for false-positive and false-negative results
(20, 84–92).
Screening test False positive False negative
Low-dose
dexamethasone
suppression test
Oral estrogens, increased CBG,
medication, rapid metabolizer,
lack of resorption of
dexamethasone
Liver or renal failure
Urine free cortisol Depended on the assay, volume
over 5 L, medications
Dependent on the assay,
GFR low, improper
collection
Salivary cortisol Age, hypertension, diabetes,
dependent on the assay,
depression, shift workers,
smokers, stress, maybe blood
-
levels do not affect it. Otherwise, oral contraception should be
paused at least 1 week but ideally for 3 months. Mitotane also
increases CBG levels and may lead to incorrect test results.
Other medications can influence the test results by induction or
inhibition of CYP 3A4. Aprepitant, itraconazole, ritonavir, and
diltiazem, for example, slow down dexamethasone metabolism
(66). Phenobarbital, phenytoin, carbamazepine, rifampicin, and
pioglitazone, however, will increase dexamethasone metabolism
(66). Additionally, individual and variable absorption and
metabolism of dexamethasone has become recently a focus
and will have an impact on test results. A measurement of
dexamethasone levels in spot urine or plasma can be helpful
to evaluate the validity of adequate resorption and metabolism
(94). Finally, liver or renal insufficiency may lead to reduced
dexamethasone clearance, which could cause a false-negative
test result.
Urine Free Cortisol (UFC)
The UFC has been used for over 50 years to diagnose CS (85).
Unlike plasma cortisol, CBG levels do not affect the results as
the free hormone is measured and not the CBG bound form.
Therefore, UFC is the preferred test for women taking oral
contraceptives. Nevertheless, different conditions can also lead
to false-positive and -negative test results. A fluid intake of over
5 L per day increases cortisol levels (95), while an incomplete
collection of the urine may cause false-negative test results. Also,
the selection of urine is not useful in patients with chronic renal
insufficiency, as UFC levels decrease with a decreasing creatinine
clearance (86). Similar to the LDDST, medication can influence
the test results. For example, carbamazepine, fenofibrate, and
TABLE 7 | Which screening method should be performed in which patient?
[adapted from Nieman et al. (66)].
Patient group Recommended
methods
False-positive
results
False-negative
results
Patients with renal
impairment
LDDST, salivary cortisol - UFC
Women under
contraception
UFC LDDST -
Smokers UFC, LDDST Salivary cortisol -
Mild or cyclic
Cushing
Repeated
measurements of UFC
and/or salivary
- LDDST
Adrenal Cushing Salivary cortisol, LDDST - UFC
Pregnancy UFC - LDDST
Patients with
epilepsy
UFC, salivary cortisol LDDST -
synthetic glucocorticoids increase UFC results. Because of day-
to-day fluctuations, current guidelines suggest collection of at
least two 24-h urines.
Depending on calibration characteristics or cross-reactivity of
first antibody with other steroids, commercial assays can both
lead to false-positive and false-negative test results (83–85, 87).
Late-Night Salivary Cortisol
The sensitivity and specificity of salivary cortisol are described in
the literature as quite high, but they are very much influenced
by the methodology. Specificity varies between 85 and 100%
depending on assay characteristics and technique. Hypertension
and diabetes can cause elevated cortisol levels in up to 40% (88)
as well as depression (89). Shift working may also be a reason
for an impaired circadian rhythm. Smoking leads to elevated
cortisol levels in saliva and should be avoided on the day of
collection (90). Bleeding or oral infections can also influence the
test results. Therefore, teeth brushing (which might lead to blood
leaks) should be avoided before sampling the salivary. Because
of a higher rate of test variability, collection of two late-night
salivary cortisol samples is recommended.
Assay Problems
To make matters worse, the test results depend on the specific
assays used to measure hormone concentrations. Basal cortisol
(96), ACTH (97), and urine cortisol (98) levels diverge by up
to 50% depending on the assays employed, heavily influencing
classification of patients. Also, salivary cortisol levels are
not comparable between assays from different manufacturers
(99). Especially in women on oral contraception, different
assays can result in highly discrepant results (100). Cortisol
levels from different laboratories are only comparable if the
same assay is used. Accordingly, recommended cutoffs and
decision limits need to be defined in an assay-specific manner.
Exemplarily, cortisol can be measured using immunoassays,
gas chromatography mass spectrometry (GC-MS), or liquid
chromatography mass spectrometry (LC-MS). Cortisol levels as
measured by the latter two methods commonly are reported
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FIGURE 1 | Overview diagnostic steps.
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to be lower (101) than those obtained by immunoassays. One
reason is that immunoassays, particularly direct ones, can suffer
from cross-reactions and thus have less specificity than the
other two methods (101). The resulting over- or underestimation
of cortisol concentrations can be a serious problem (96).
Nevertheless, in clinical routine, immunoassays still are the
most frequently used method (101). The same problems
apply to the use of salivary cortisol, where concentrations
measured by LC-MS and immunoassays exhibit poor agreement
(92, 101).
SUMMARY OF THE FIRST-LINE
SCREENING
Figure 1 gives an overview about the first-line-screening-
steps. The following rules are essential regarding the first-line-
screening:
1. Biochemical screening should only be conducted when the
patient has clinical features suggesting CS.
2. At least two tests should be conducted.
3. False-negative and false-positive results are likely. A positive
test result is therefore not a proof for a CS.
4. When in doubt, biochemical screening should be repeated.
EXCEPTIONAL CASES: DIAGNOSTICS IN
MILD AND EPISODIC CS
Severe hypercortisolism can be relatively easily detected using the
tests mentioned above. Mild or cyclic CS, however, requires a
different procedure. Recent studies suggest that mild or episodic
hypercortisolism is more frequent than assumed (102). In these
cases, the clinical signs or symptoms of the patient are even more
critical. If clinically a CS is likely, a single negative test should not
lead to the exclusion of an endogenous hypercortisolism. Short-
term follow-ups are essential to confirm or exclude the diagnosis.
Diagnosing patients with just a few—or maybe even one—
“Cushing symptoms” can be challenging as well. It is important to
consider CS as a possible differential diagnosis in young patients
with osteoporosis, hypertension, or even mental disorders that
cannot be explained by anything else.
Just a few studies focused on cyclic CS so far. Generally,
repeating the sampling of urine or salivary is recommended
while the LDDST is less useful (102, 103). We recommend
to carefully take a history in these patients to investigate
whether they can identify a time pattern in their symptoms.
Additionally, as it can be easily conducted at home, these
patients should collect salivary samples or urine over a longer
time period. Also, measuring cortisol in the hair has been
advocated to detect cyclic CS (104). This assay is currently not
commercially available.
NEW APPROACHES: PLASMA STEROID
METABOLOME PROFILING
Using LC-MS, we recently explored the diagnostic accuracy
of steroid profiling of basal plasma samples from patients
with CS. A panel of 15 plasma steroids were applied to
222 patient samples tested for CS. Disease was excluded in
138 and confirmed in 51 patients with pituitary CS, 12 with
ectopic adrenocorticotropin secretion, and 21 with adrenal CS.
We identified distinct steroid profiles among patients with
CS that separated patients from healthy controls. Moreover,
classification into the three Cushing subtypes was achieved
with reasonable accuracy. With the use of 10 selected steroids,
subjects with and without different CS subtypes could be
discriminated nearly as good as with the use of a combination
of the three conventional screening tests and plasma ACTH
(misclassification of 9.5% of subjects with steroid profiling vs.
5.8% with conventional testing) (105). In another study, we
demonstrated that the 15-plasma-steroid panel was able to
discriminate 35 patients with subclinical CS from 21 with overt
clinical CS and normal controls. Patients with subclinical CS
had lower plasma concentrations of dehydroepiandrosterone and
dehydroepiandrosterone-sulfate than normal subjects, but higher
levels of 11-deoxycortisol and 11-deoxycorticosterone. The
steroid combination provided superior diagnostic performance
compared to each of the other routine biochemical tests (106).
These data are in line with recent data obtained in patients
with primary aldosteronism (107) and could pave the way to
simplified biochemical confirmation of steroid excess syndromes
if confirmed by other studies.
CONCLUSION AND OUTLOOK
Diagnosing CS is not straightforward: it remains challenging
to preselect patients with an increased likelihood of CS
and to select the best biochemical screening test for a
given patient. Undoubtedly, current clinical and biochemical
screening approaches are far from ideal, and simplified
procedures are required from both a patient’s and a physician’s
perspective. The clinical score by Leon-Justel could be a good
starting point but it should be validated in other patient
cohorts. Other laboratory tests like plasma steroid profiling
are promising approaches to reduce the number of diagnostic
tests (105).
To conclude, we suggest a rational clinical score for
patients with CS: based on the scores by Leon-Justel and
Nugent and the results from different screening studies, the
following clinical signs should be included in a clinical score:
osteoporosis, muscular atrophy [objectively assessed by a
combination of the chair rising test, hand-grip measurement,
and the bioelectrical impedance measurement (8)], livid
striae, plethora, ecchymoses, and dorsocervical fat pat.
Such a clinical score should be validated comparing a
cohort of patients with CS and patients with an initial
clinical suspicion for hypercortisolism in which CS
was excluded.
AUTHOR CONTRIBUTIONS
LB and MR have written the first draft of the manuscript. AR,
AO-K, JF, GR, MB, and FB substantially contributed to the
revision of the manuscript. All authors read and approved the
final version for submission.
Frontiers in Endocrinology | www.frontiersin.org 9 November 2019 | Volume 10 | Article 766
Braun et al. Diagnostics in Cushing’s Syndrome
REFERENCES
1. Steffensen C, Bak AM, Rubeck KZ, Jorgensen JO. Epidemiology of
Cushing’s syndrome. Neuroendocrinology. (2010) 92 (Suppl. 1):1–5.
doi: 10.1159/000314297
2. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing’s
syndrome. Lancet. (2006) 367:1605–17. doi: 10.1016/S0140-6736(06)
68699-6
3. Debono M, Newell-Price JD. Cushing’s syndrome: where and how to find it.
Front Horm Res. (2016) 46:15–27. doi: 10.1159/000443861
4. Kreitschmann-Andermahr I, Psaras T, Tsiogka M, Starz D, Kleist B, Siegel S,
et al. From first symptoms to final diagnosis of Cushing’s disease: experiences
of 176 patients. Eur J Endocrinol. (2015) 172:X1. doi: 10.1530/EJE-14-0766
5. Javanmard P, Duan D, Geer EB. Mortality in patients with endogenous
Cushing’s syndrome. Endocrinol Metab Clin North Am. (2018) 47:313–33.
doi: 10.1016/j.ecl.2018.02.005
6. Valassi E, Tabarin A, Brue T, Feelders RA, Reincke M, Netea-Maier R,
et al. High mortality within 90 days of diagnosis in patients with Cushing’s
syndrome - Results from the ERCUSYN registry. Eur J Endocrinol. (2019)
181:461–72. doi: 10.1530/EJE-19-0464
7. Berr CM, Di Dalmazi G, Osswald A, Ritzel K, Bidlingmaier M, Geyer LL,
et al. Time to recovery of adrenal function after curative surgery for Cushing’s
syndrome depends on etiology. J Clin Endocrinol Metab. (2015) 100:1300–8.
doi: 10.1210/jc.2014-3632
8. Berr CM, Stieg MR, Deutschbein T, Quinkler M, Schmidmaier R, Osswald
A, et al. Persistence of myopathy in Cushing’s syndrome: evaluation of
the German Cushing’s Registry. Eur J Endocrinol. (2017) 176:737–46.
doi: 10.1530/EJE-16-0689
9. Osswald A, Deutschbein T, Berr CM, Plomer E, Mickisch A, Ritzel K, et al.
Surviving ectopic Cushing’s syndrome: quality of life, cardiovascular and
metabolic outcomes in comparison to Cushing’s disease during long-term
follow-up. Eur J Endocrinol. (2018) 179:109–16. doi: 10.1530/EJE-18-0212
10. Rubinstein G, Osswald A, Hoster E, Losa M, Elenkova A, Zacharieva S, et al.
Time to diagnosis in Cushing’s syndrome: a meta-analysis based on 5367
patients. J Clin EndocrinolMetab. (2019) dgz136. doi: 10.1210/clinem/dgz136
11. Elstein AS, Shulman LS, Sprafka SA. Medical Problem Solving an Analysis
of Clinical Reasoning. Cambridge: Harvard University Press (1978).
doi: 10.4159/harvard.9780674189089
12. Braun LT, Zottmann JM, Adolf C, Lottspeich C, Then C, Wirth S, et al.
Representation scaffolds improve diagnostic efficiency in medical students.
Med Educ. (2017) 51:1118–26. doi: 10.1111/medu.13355
13. Graber ML, Carlson B. Diagnostic error: the hidden epidemic. Physician
Exec. (2011) 37:12–4, 6, 8–9.
14. Zwaan L, de Bruijne M, Wagner C, Thijs A, Smits M, van der Wal
G, et al. Patient record review of the incidence, consequences, and
causes of diagnostic adverse events. Arch Intern Med. (2010) 170:1015–21.
doi: 10.1001/archinternmed.2010.146
15. Graber ML, Franklin N, Gordon R. Diagnostic error in internal medicine.
Arch Intern Med. (2005) 165:1493–9. doi: 10.1001/archinte.165.13.1493
16. Schmidt HG, Rikers RM. How expertise develops in medicine: knowledge
encapsulation and illness script formation. Med Educ. (2007) 41:1133–9.
doi: 10.1111/j.1365-2923.2007.02915.x
17. Custers EJ. Thirty years of illness scripts: theoretical origins
and practical applications. Med Teach. (2015) 37:457–62.
doi: 10.3109/0142159X.2014.956052
18. Nugent CA, Warner HR, Dunn JT, Tyler FH. Probability theory in the
diagnosis of Cushing’s syndrome. J Clin Endocrinol Metab. (1964) 24:621–7.
doi: 10.1210/jcem-24-7-621
19. Valassi E, Santos A, Yaneva M, Toth M, Strasburger CJ, Chanson P, et al.
The European Registry on Cushing’s syndrome: 2-year experience. Baseline
demographic and clinical characteristics. Eur J Endocrinol. (2011) 165:383–
92. doi: 10.1530/EJE-11-0272
20. Sharma ST, Nieman LK, Feelders RA. Cushing’s syndrome: epidemiology
and developments in disease management. Clin Epidemiol. (2015) 7:281–93.
doi: 10.2147/CLEP.S44336
21. Feelders RA, Pulgar SJ, Kempel A, Pereira AM. The burden of Cushing’s
disease: clinical and health-related quality of life aspects. Eur J Endocrinol.
(2012) 167:311–26. doi: 10.1530/EJE-11-1095
22. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al.
Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001.
JAMA. (2003) 289:76–9. doi: 10.1001/jama.289.1.76
23. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres
M, et al. Hypertension prevalence and blood pressure levels in 6 European
countries, Canada, and the United States. JAMA. (2003) 289:2363–9.
doi: 10.1001/jama.289.18.2363
24. DunstanDW, Zimmet PZ,Welborn TA, De CourtenMP, Cameron AJ, Sicree
RA, et al. The rising prevalence of diabetes and impaired glucose tolerance:
the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care. (2002)
25:829–34. doi: 10.2337/diacare.25.5.829
25. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence
of diabetes for 2010 and 2030. Diab Res Clin Pract. (2010) 87:4–14.
doi: 10.1016/j.diabres.2009.10.007
26. Reginster J-Y, Burlet N. Osteoporosis: a still increasing prevalence. Bone.
(2006) 38:4–9. doi: 10.1016/j.bone.2005.11.024
27. Kit BK, Kuklina E, Carroll MD, Ostchega Y, Freedman DS, Ogden CL.
Prevalence of and trends in dyslipidemia and blood pressure among US
children and adolescents, 1999–2012. JAMA Pediatrics. (2015) 169:272–9.
doi: 10.1001/jamapediatrics.2014.3216
28. Elton RF, Pinkus H. Striae in normal men. Arch Dermatol. (1966) 94:33–4.
doi: 10.1001/archderm.1966.01600250039005
29. Prati P, Vanuzzo D, Casaroli M, Di Chiara A, De Biasi F, Feruglio GA,
et al. Prevalence and determinants of carotid atherosclerosis in a general
population. Stroke. (1992) 23:1705–11. doi: 10.1161/01.STR.23.12.1705
30. Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. J Am
Acad Dermatol. (1999) 41:577–80. doi: 10.1016/S0190-9622(99)70300-2
31. Falsetti L, Gambera A, Andrico S, Sartori E. Acne and hirsutism
in polycystic ovary syndrome: clinical, endocrine–metabolic and
ultrasonographic differences. Gynecol Endocrinol. (2002) 16:275–84.
doi: 10.1080/gye.16.4.275.284
32. Feigin VL, Lawes CM, Bennett DA, Anderson CS. Stroke epidemiology:
a review of population-based studies of incidence, prevalence, and
case-fatality in the late 20th century. Lancet Neurol. (2003) 2:43–53.
doi: 10.1016/S1474-4422(03)00266-7
33. Gößwald A, Schienkiewitz A, Nowossadeck E, Busch M. Prävalenz von
Herzinfarkt und koronarer Herzkrankheit bei Erwachsenen im Alter von 40
bis 79 Jahren in Deutschland. Bundesgesundheitsblatt-Gesundheitsforschung-
Gesundheitsschutz. (2013) 56:650–5. doi: 10.1007/s00103-013-1666-9
34. Ayuso-Mateos JL, Vázquez-Barquero JL, Dowrick C, LehtinenV, DalgardOS,
Casey P, et al. Depressive disorders in Europe: prevalence figures from the
ODIN study. Br J Psychiatry. (2001) 179:308–16. doi: 10.1192/bjp.179.4.308
35. Kelly WF, Kelly MJ, Faragher B. A prospective study of psychiatric
and psychological aspects of Cushing’s syndrome. Clin Endocrinol. (1996)
45:715–20. doi: 10.1046/j.1365-2265.1996.8690878.x
36. Djernes JK. Prevalence and predictors of depression in populations
of elderly: a review. Acta Psychiatr Scand. (2006) 113:372–87.
doi: 10.1111/j.1600-0447.2006.00770.x
37. Tiemensma J, Kokshoorn NE, Biermasz NR, Keijser BJ, Wassenaar MJ,
Middelkoop HA, et al. Subtle cognitive impairments in patients with long-
term cure of Cushing’s disease. J Clin Endocrinol Metab. (2010) 95:2699–714.
doi: 10.1210/jc.2009-2032
38. Starkman MN, Gebarski SS, Berent S, Schteingart DE. Hippocampal
formation volume, memory dysfunction, and cortisol levels in
patients with Cushing’s syndrome. Biol Psychiatry. (1992) 32:756–65.
doi: 10.1016/0006-3223(92)90079-F
39. Diehm C, Noppeney T, Nüllen H. Epidemiologie der
venösen Thromboembolie. Gefässchirurgie. (2012) 17:275–9.
doi: 10.1007/s00772-011-0929-8
40. Walther A, Böttiger B. Die akute Lungenarterienembolie. Der Anaesthesist.
(2002) 51:427–46. doi: 10.1007/s00101-002-0315-8
41. Ramello A, Vitale C, Marangella M. Epidemiology of nephrolithiasis. J
Nephrol. (2001) 13:S45–50.
42. Holick MF. Vitamin D deficiency. N Engl J Med. (2007) 357:266–81.
doi: 10.1056/NEJMra070553
43. Foxman B. Epidemiology of urinary tract infections: incidence,
morbidity, and economic costs. Am J Med. (2002) 113:5–13.
doi: 10.1016/S0002-9343(02)01054-9
Frontiers in Endocrinology | www.frontiersin.org 10 November 2019 | Volume 10 | Article 766
Braun et al. Diagnostics in Cushing’s Syndrome
44. Ram S, Seirawan H, Kumar SK, Clark GT. Prevalence and impact of sleep
disorders and sleep habits in the United States. Sleep Breath. (2010) 14:63–70.
doi: 10.1007/s11325-009-0281-3
45. De Rose AF, Gallo F, Bini PM, Gattuccio I, Chiriaco V, Terrone C.
Epidemiology of sexual disorders in general medical practice: an Italian
survey. Urologia. (2019) 86:79–85. doi: 10.1177/0391560319842955
46. Gan DC, Sinclair RD. Prevalence of male and female pattern hair
loss in Maryborough. J Investig Dermatol Symp Proc. (2005) 10:184–9.
doi: 10.1111/j.1087-0024.2005.10102.x
47. Leon-Justel A, Madrazo-Atutxa A, Alvarez-Rios AI, Infantes-Fontan R,
Garcia-Arnes JA, Lillo-Munoz JA, et al. A probabilistic model for Cushing’s
syndrome screening in at-risk populations: a prospective multicenter study.
J Clin Endocrinol Metab. (2016) 101:3747–54. doi: 10.1210/jc.2016-1673
48. Learned-Miller E, Lu Q, Paisley A, Trainer P, Blanz V, Dedden K,
et al. Detecting acromegaly: screening for disease with a morphable
model. Med Image Comput Comput Assist Interv. (2006) 9(Pt 2):495–503.
doi: 10.1007/11866763_61
49. Schneider HJ, Kosilek RP, GuntherM, Roemmler J, Stalla GK, Sievers C, et al.
A novel approach to the detection of acromegaly: accuracy of diagnosis by
automatic face classification. J Clin Endocrinol Metab. (2011) 96:2074–80.
doi: 10.1210/jc.2011-0237
50. Kosilek RP, Schopohl J, Grunke M, Reincke M, Dimopoulou C, Stalla GK,
et al. Automatic face classification of Cushing’s syndrome in women - a
novel screening approach. Exp Clin Endocrinol Diabetes. (2013) 121:561–4.
doi: 10.1055/s-0033-1349124
51. Kosilek RP, Frohner R, Wurtz RP, Berr CM, Schopohl J, Reincke M, et al.
Diagnostic use of facial image analysis software in endocrine and genetic
disorders: review, current results and future perspectives. Eur J Endocrinol.
(2015) 173:M39–44. doi: 10.1530/EJE-15-0429
52. Popp KH, Kosilek RP, Frohner R, Stalla GK, Athanasoulia-Kaspar A,
Berr C, et al. Computer vision technology in the differential diagnosis
of Cushing’s syndrome. Exp Clin Endocrinol Diabetes. (2019) 127:685–90.
doi: 10.1055/a-0887-4233
53. Reimondo G, Pia A, Allasino B, Tassone F, Bovio S, Borretta G,
et al. Screening of Cushing’s syndrome in adult patients with
newly diagnosed diabetes mellitus. Clin Endocrinol. (2007) 67:225–9.
doi: 10.1111/j.1365-2265.2007.02865.x
54. Mullan K, BlackN, Thiraviaraj A, Bell PM, Burgess C, Hunter SJ, et al. Is there
value in routine screening for Cushing’s syndrome in patients with diabetes?
J Clin Endocrinol Metab. (2010) 95:2262–5. doi: 10.1210/jc.2009-2453
55. Terzolo M, Reimondo G, Chiodini I, Castello R, Giordano R, Ciccarelli E,
et al. Screening of Cushing’s syndrome in outpatients with type 2 diabetes:
results of a prospective multicentric study in Italy. J Clin Endocrinol Metab.
(2012) 97:3467–75. doi: 10.1210/jc.2012-1323
56. Tabarin A, Perez P. Pros and cons of screening for occult Cushing syndrome.
Nat Rev Endocrinol. (2011) 7:445. doi: 10.1038/nrendo.2011.51
57. Anderson GH Jr, Blakeman N, Streeten DH. The effect of age on prevalence
of secondary forms of hypertension in 4429 consecutively referred patients.
J Hypertens. (1994) 12:609–15. doi: 10.1097/00004872-199405000-00015
58. Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study
on the prevalence of secondary hypertension among hypertensive patients
visiting a general outpatient clinic in Japan. Hypertens Res. (2004) 27:193–
202. doi: 10.1291/hypres.27.193
59. Tiryakioglu O, Ugurlu S, Yalin S, Yirmibescik S, Caglar E, Yetkin DO, et al.
Screening for Cushing’s syndrome in obese patients. Clinics. (2010) 65:9–13.
doi: 10.1590/S1807-59322010000100003
60. Baid SK, Rubino D, Sinaii N, Ramsey S, Frank A, Nieman LK.
Specificity of screening tests for Cushing’s syndrome in an overweight
and obese population. J Clin Endocrinol Metab. (2009) 94:3857–64.
doi: 10.1210/jc.2008-2766
61. Shimon I. Screening for Cushing’s syndrome: is it worthwhile? Pituitary.
(2015) 18:201–5. doi: 10.1007/s11102-015-0634-9
62. Chiodini I, Mascia ML, Muscarella S, Battista C, Minisola S,
Arosio M, et al. Subclinical hypercortisolism among outpatients
referred for osteoporosis. Ann Intern Med. (2007) 147:541–8.
doi: 10.7326/0003-4819-147-8-200710160-00006
63. Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, et al.
Management of adrenal incidentalomas: European Society of Endocrinology
Clinical Practice Guideline in collaboration with the European Network
for the Study of Adrenal Tumors. Eur J Endocrinol. (2016) 175:G1–g34.
doi: 10.1530/EJE-16-0467
64. Nieman LK. Approach to the patient with an adrenal incidentaloma. J Clin
Endocrinol Metab. (2010) 95:4106–13. doi: 10.1210/jc.2010-0457
65. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome
among US adults: findings from the third National Health and Nutrition
Examination Survey. JAMA. (2002) 287:356–9. doi: 10.1001/jama.287.3.356
66. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart
PM, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society
Clinical Practice Guideline. J Clin Endocrinol Metab. (2008) 93:1526–40.
doi: 10.1210/jc.2008-0125
67. Nieman LK. Cushing’s syndrome: update on signs, symptoms
and biochemical screening. Eur J Endocrinol. (2015) 173:M33–8.
doi: 10.1530/EJE-15-0464
68. Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates,
disability, and comorbidity of DSM-IV alcohol abuse and dependence in
the United States: results from the National Epidemiologic Survey on
Alcohol and Related Conditions. Arch Gen Psychiatry. (2007) 64:830–42.
doi: 10.1001/archpsyc.64.7.830
69. Barker L, Gout B, Crowe T. Hospital malnutrition: prevalence, identification
and impact on patients and the healthcare system. Int J Environ Res Public
Health. (2011) 8:514–27. doi: 10.3390/ijerph8020514
70. Giraldi FP, Moro M, Cavagnini F, Endocrinology SGotH-P-AAotISo.
Gender-related differences in the presentation and course of
Cushing’s disease. J Clin Endocrinol Metab. (2003) 88:1554–8.
doi: 10.1210/jc.2002-021518
71. Stratakis CA. Skin manifestations of Cushing’s syndrome. Rev Endocr Metab
Disord. (2016) 17:283–6. doi: 10.1007/s11154-016-9399-3
72. Elsaie ML, Baumann LS, Elsaaiee LT. Striae distensae (stretch marks) and
different modalities of therapy: an update. Dermatol Surg. (2009) 35:563–73.
doi: 10.1111/j.1524-4725.2009.01094.x
73. Ross EJ, Linch DC. Cushing’s syndrome–killing disease: discriminatory value
of signs and symptoms aiding early diagnosis. Lancet. (1982) 2:646–9.
doi: 10.1016/S0140-6736(82)92749-0
74. Afshari A, Ardeshirpour Y, Lodish MB, Gourgari E, Sinaii N, Keil M,
et al. Facial plethora: modern technology for quantifying an ancient clinical
sign and its use in Cushing syndrome. J Clin Endocrinol Metab. (2015)
100:3928–33. doi: 10.1210/jc.2015-2497
75. Vestergaard P, Lindholm J, Jorgensen JO, Hagen C, Hoeck HC, Laurberg
P, et al. Increased risk of osteoporotic fractures in patients with
Cushing’s syndrome. Eur J Endocrinol. (2002) 146:51–6. doi: 10.1530/eje.0.14
60051
76. Belaya ZE, Hans D, Rozhinskaya LY, Dragunova NV, Sasonova NI,
Solodovnikov AG, et al. The risk factors for fractures and trabecular
bone-score value in patients with endogenous Cushing’s syndrome. Arch
Osteoporos. (2015) 10:44. doi: 10.1007/s11657-015-0244-1
77. Stewart PM, Walker BR, Holder G, O’Halloran D, Shackleton
CH. 11 beta-Hydroxysteroid dehydrogenase activity in Cushing’s
syndrome: explaining the mineralocorticoid excess state of the ectopic
adrenocorticotropin syndrome. J Clin Endocrinol Metab. (1995) 80:3617–20.
doi: 10.1210/jc.80.12.3617
78. Doerr P, Pirke KM. Cortisol-induced suppression of plasma testosterone
in normal adult males. J Clin Endocrinol Metab. (1976) 43:622–9.
doi: 10.1210/jcem-43-3-622
79. Sabag N, Castrillon M, Tchernitchin A. Cortisol-induced migration of
eosinophil leukocytes to lymphoid organs. Experientia. (1978) 34:666–7.
doi: 10.1007/BF01937022
80. Faggiano A, Pivonello R, Melis D, Filippella M, Di Somma C, Petretta M,
et al. Nephrolithiasis in Cushing’s Disease: prevalence, etiopathogenesis, and
modification after disease cure. J Clin Endocrinol Metab. (2003) 88:2076–80.
doi: 10.1210/jc.2002-021494
81. Hurxthal LM, O’sullivan JB. Cushing’s syndrome: clinical differential
diagnosis and complications. Ann Intern Med. (1959) 51:1–16.
doi: 10.7326/0003-4819-51-1-1
82. Gursoy A, Unal AD, Ayturk S, Karakus S, Izol AN, Tutuncu NB, et al.
Polycythemia as the first manifestation of Cushing’s disease. J Endocrinol
Invest. (2006) 29:742–4. doi: 10.1007/BF03344186
Frontiers in Endocrinology | www.frontiersin.org 11 November 2019 | Volume 10 | Article 766
Braun et al. Diagnostics in Cushing’s Syndrome
83. Reimondo G, Pia A, Bovio S, Allasino B, Daffara F, Paccotti P, et al.
Laboratory differentiation of Cushing’s syndrome. Clin Chim Acta. (2008)
388:5–14. doi: 10.1016/j.cca.2007.10.036
84. Elias PC, Martinez EZ, Barone BF, Mermejo LM, Castro M, Moreira AC.
Late-night salivary cortisol has a better performance than urinary free
cortisol in the diagnosis of Cushing’s syndrome. J Clin Endocrinol Metab.
(2014) 99:2045–51. doi: 10.1210/jc.2013-4262
85. Raff H, Auchus RJ, Findling JW, Nieman LK. Urine free cortisol in the
diagnosis of Cushing’s syndrome: is it worth doing and, if so, how? J Clin
Endocrinol Metab. (2015) 100:395–7. doi: 10.1210/jc.2014-3766
86. Chan KC, Lit LC, Law EL, Tai MH, Yung CU, Chan MH,
et al. Diminished urinary free cortisol excretion in patients with
moderate and severe renal impairment. Clin Chem. (2004) 50:757–9.
doi: 10.1373/clinchem.2003.029934
87. Kidambi S, Raff H, Findling JW. Limitations of nocturnal salivary cortisol
and urine free cortisol in the diagnosis of mild Cushing’s syndrome. Eur J
Endocrinol. (2007) 157:725–31. doi: 10.1530/EJE-07-0424
88. Liu H, Bravata DM, Cabaccan J, Raff H, Ryzen E. Elevated late-night salivary
cortisol levels in elderly male type 2 diabetic veterans.Clin Endocrinol. (2005)
63:642–9. doi: 10.1111/j.1365-2265.2005.02395.x
89. Butler P, Besser G. Pituitary-adrenal function in severe depressive illness.
Lancet. (1968) 291:1234–6. doi: 10.1016/S0140-6736(68)91927-2
90. Badrick E, Kirschbaum C, Kumari M. The relationship between smoking
status and cortisol secretion. J Clin Endocrinol Metab. (2007) 92:819–24.
doi: 10.1210/jc.2006-2155
91. Nickelsen T, Lissner W, Schöﬄing K. The dexamethasone suppression test
and long-term contraceptive treatment: measurement of ACTH or salivary
cortisol does not improve the reliability of the test. Exp Clin Endocrinol
Diabetes. (1989) 94:275–80. doi: 10.1055/s-0029-1210910
92. Baid SK, Sinaii N, Wade M, Rubino D, Nieman LK. Radioimmunoassay and
tandemmass spectrometrymeasurement of bedtime salivary cortisol levels: a
comparison of assays to establish hypercortisolism. J Clin Endocrinol Metab.
(2007) 92:3102–7. doi: 10.1210/jc.2006-2861
93. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S,
et al. Accuracy of diagnostic tests for Cushing’s syndrome: a systematic
review and metaanalyses. J Clin Endocrinol Metab. (2008) 93:1553–62.
doi: 10.1210/jc.2008-0139
94. Meikle AW. Dexamethasone suppression tests: usefulness of simultaneous
measurement of plasma cortisol and dexamethasone. Clin Endocrinol. (1982)
16:401–8. doi: 10.1111/j.1365-2265.1982.tb00733.x
95. Mericq MV, Cutler GB Jr. High fluid intake increases urine free cortisol
excretion in normal subjects. J Clin Endocrinol Metab. (1998) 83:682–4.
doi: 10.1210/jcem.83.2.4555
96. Briegel J, Sprung CL, Annane D, Singer M, Keh D, Moreno R, et al.
Multicenter comparison of cortisol as measured by different methods in
samples of patients with septic shock. Intensive Care Med. (2009) 35:2151–6.
doi: 10.1007/s00134-009-1627-9
97. Pecori Giraldi F, Saccani A, Cavagnini F. Assessment of ACTH assay
variability: a multicenter study. Eur J Endocrinol. (2011) 164:505–12.
doi: 10.1530/EJE-10-0962
98. Galeandro L, Sieber-Ruckstuhl NS, Riond B, Hartnack S, Hofmann-
Lehmann R, Reusch CE, et al. Urinary corticoid concentrations measuredby
5 different immunoassays and gas chromatography-mass spectrometry
in healthy dogs and dogs with hypercortisolism at home and in
the hospital. J Vet Intern Med. (2014) 28:1433–41. doi: 10.1111/jvim.
12399
99. Miller R, Plessow F, Rauh M, Groschl M, Kirschbaum C. Comparison
of salivary cortisol as measured by different immunoassays and
tandem mass spectrometry. Psychoneuroendocrinology. (2013) 38:50–7.
doi: 10.1016/j.psyneuen.2012.04.019
100. Klose M, Lange M, Rasmussen AK, Skakkebaek NE, Hilsted L, Haug
E, et al. Factors influencing the adrenocorticotropin test: role of
contemporary cortisol assays, body composition, and oral contraceptive
agents. J Clin Endocrinol Metab. (2007) 92:1326–33. doi: 10.1210/jc.20
06-1791
101. Turpeinen U, Hamalainen E. Determination of cortisol in serum, saliva
and urine. Best Pract Res Clin Endocrinol Metab. (2013) 27:795–801.
doi: 10.1016/j.beem.2013.10.008
102. Friedman TC, Ghods DE, Shahinian HK, Zachery L, Shayesteh N, Seasholtz
S, et al. High prevalence of normal tests assessing hypercortisolism in
subjects with mild and episodic Cushing’s syndrome suggests that the
paradigm for diagnosis and exclusion of Cushing’s syndrome requires
multiple testing. Horm Metab Res. (2010) 42:874–81. doi: 10.1055/s-0030-12
63128
103. Velez DA, Mayberg MR, LudlamWH. Cyclic Cushing syndrome: definitions
and treatment implications. Neurosurg Focus. (2007) 23:E4; discussion Ea.
doi: 10.3171/foc.2007.23.3.5
104. Wester VL, Reincke M, Koper JW, van den Akker ELT, Manenschijn L, Berr
CM, et al. Scalp hair cortisol for diagnosis of Cushing’s syndrome. Eur J
Endocrinol. (2017) 176:695–703. doi: 10.1530/EJE-16-0873
105. Eisenhofer G, Masjkur J, Peitzsch M, Di Dalmazi G, Bidlingmaier M,
Gruber M, et al. Plasma steroid metabolome profiling for diagnosis and
subtyping patients with Cushing syndrome. Clin Chem. (2018) 64:586–96.
doi: 10.1373/clinchem.2017.282582
106. Masjkur J, Gruber, M, Peitzsch, M, Kaden, D, Di Dalmazi G, Bidlingmaier
M, et al. Plasma steroid profiles in subclinical compared with overt
adrenal cushing syndrome. J Clin Endocrinol Metab. (2019) 104:4331–40.
doi: 10.1210/jc.2018-02349
107. Eisenhofer G, Dekkers T, Peitzsch M, Dietz AS, Bidlingmaier M, Treitl
M, et al. Mass spectrometry-based adrenal and peripheral venous steroid
profiling for subtyping primary aldosteronism.Clin Chem. (2016) 62:514–24.
doi: 10.1373/clinchem.2015.251199
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2019 Braun, Riester, Oßwald-Kopp, Fazel, Rubinstein, Bidlingmaier,
Beuschlein and Reincke. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Endocrinology | www.frontiersin.org 12 November 2019 | Volume 10 | Article 766
